FDA: New Warning for Procrit, Epogen, Aranesp

New data show that the way Procrit, Epogen, and Aranesp are used in patients with chronic kidney disease puts them at risk of heart attacks, stroke, and death. More conservative dosing is needed.

Click here to read the full story.

Post a Comment

Comments

No comments yet!

Heart Disease

Cardiac Arrest Risk Low in Marathons, Study Finds
4 Simple Steps to a Healthy Heart
U.S. Heart Health: Lots of Room for Improvement
Study Finds Benefits in Selective Use of Drug-Coated Stents
Fat Around Heart May Be Linked to Clogged Arteries

Fibromyalgia

Antidepressants Help Treat Fibromyalgia
FDA OKs Fibromyalgia Drug Savella
Naltrexone May Ease Fibromyalgia Symptoms
Retrovirus Linked to Chronic Fatigue Syndrome
Short Bursts of Activity Ease Fibromyalgia

Depression

Study: Mental Health Is Top Concern for Youth
Video Game May Help Treat Teen Depression
Antidepressants Aid Depressed Parkinson's Patients
Cymbalta May Relieve Chemo-induced Pain, Tingling
Depression Treatment by Phone

Cholesterol

Personality Secrets to a Long Life
A Wake-Up Call: All Children Should Be Tested for High Cholesterol
Kids’ Lifestyle Changes Bring Later Heart Health
Added Sugar May Raise Cholesterol in Teens
Americans Don't Do Enough to Cut Hypertension, Cholesterol

Sleep Disorders

Preschoolers Who Sleep Less Weigh More by Age 7
When Wives Don’t Sleep, Marriage Suffers
Alcohol at Bedtime May Not Help Your Sleep
Sleepy Americans Put Health at Risk
Sleep and Technology Don't Mix: Sleep Poll

Migraines

Migraines Reduce Workplace Productivity
High-Flow Oxygen Treats Cluster Headaches
Why Light Worsens Migraine Headaches
Migraines, Depression: A Genetic Link?
Migraines Linked to Heart Attack Risk

The Health News section does not provide medical advice, diagnosis or treatment. See additional information.

This site is hosted and managed by Inergize Digital.
Mobile advertising for this site is available on Local Ad Buy.